Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma With High-Dose Cyclophosphamide, Total Body Irradiation and Involved-Field Radiation Therapy

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease or non-Hodgkin's lymphoma
that is refractory to standard therapy or has relapsed following initial response Eligible
non-Hodgkin's lymphoma: Low grade Intermediate grade Immunoblastic large cell lymphoma
(high grade) Eligible for involved field radiotherapy, cyclophosphamide, and total body
irradiation No CNS non-Hodgkin's lymphoma or Hodgkin's disease A new classification scheme
for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or
"aggressive" lymphoma will replace the former terminology of "low", "intermediate", or
"high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS: Age: Physiologic age 65 and under Performance status: ECOG 0-2
Life expectancy: At least 2 months Hematopoietic: Not specified Hepatic: Not specified
Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 50 mL/min if
creatinine 1.5-2 mg/dL Cardiovascular: No active heart disease (congestive heart failure,
history of myocardial infarction within the past 3 months, or significant arrhythmia)
requiring medication Pulmonary: No nonneoplastic pulmonary disease (e.g., chronic
obstructive pulmonary disease) that would preclude intensive chemotherapy DLCO at least
50% predicted* FEV1 and/or FVC at least 75% predicted* * Unless due to underlying lymphoma
or Hodgkin's disease Other: No other concurrent medical condition that would preclude
aggressive cytotoxic chemotherapy HIV negative No clinical evidence of AIDS

PRIOR CONCURRENT THERAPY: See Disease Characteristics